Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
| Autor: | Věra VozobulovÁ, Radana Neuwirtova, Jaroslav Cermak, Anna Jonasova, I. Hochová, M. Siskova, K. Mociková |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Hypoplastic anemia Combination therapy business.industry medicine.medical_treatment Hematology Ciclosporin Gastroenterology Surgery medicine.anatomical_structure Refractory Erythropoietin Cyclosporin a Internal medicine medicine Bone marrow business medicine.drug |
| Zdroj: | British Journal of Haematology. 100:304-309 |
| ISSN: | 0007-1048 |
| DOI: | 10.1046/j.1365-2141.1998.00551.x |
| Popis: | We report 17 cytopenic patients with myelodysplastic syndrome (MDS) of refractory anaemia (RA) subtype with hyper-, normo- or hypo-cellular bone marrow (BM), who were treated with cyclosporin A (CyA). Substantial haematological response was observed in 14 patients (82%): their anaemia improved and all transfusion-dependent patients achieved transfusion independence. Complete trilineage recovery was observed in four patients (23%). The CyA therapy has not yet failed in any of the 14 successfully treated patients during follow-up times ranging from 5 to 30 months. CyA was well tolerated in 14 patients; serious side-effects required termination of the therapy in three patients in whom the blood count rapidly deteriorated to former levels upon cessation of therapy. Two patients benefited from a combination therapy of CyA and erythropoietin. Six patients experienced various autoimmune phenomena. CyA could thus offer an alternative treatment for certain MDS patients with RA regardless of hyper-, normo- or hypo-cellularity of bone marrow (BM). The mechanism of the beneficial effect of CyA is discussed and remains the subject of an ongoing study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text